Only 35 percent reported an ECG in the previous year and 46 percent said they had an ECG in the previous five years, reducing the possibility that the low number of cardiac
events stemmed from at -
risk runners being screened out before the race.
Myelosuppression is a well - established side effect of current AML therapies, with prolonged
events leading to an increased
risk of infections and death.44 Consequently, therapies that preferentially kill leukemic cells over normal bone marrow cells are urgently required, and the overexpression of CD123 on AML leukemic
stem cells and blasts compared with normal hematopoietic cells contributes to its attractiveness as a therapeutic target in this disease.6, 45 However, severe myelosuppression and myeloablation have emerged for some investigational CD123 - targeted treatment modalities.